Short answer
Perspective Therapeutics, Inc. (CATX) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$26M
- −71.7% YoY · −20.9% QoQ
- EPS (diluted)
- −$0.35
- −66.7% YoY · −20.7% QoQ
Source: XBRL data from the Perspective Therapeutics, Inc. (CATX) Q3 2025 10-Q on SEC EDGAR. USD.
Perspective Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Risk Factors section not provided; no new or changed risks identifiable
- Executive leadership transition: Joel Sendek employment agreement effective September 4, 2025
- Executive departure exposure: Juan Graham separation agreement effective September 24, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Perspective Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.